Discontinuation due to side effects ran at 7% in Phase 2 data, which is lower than Semaglutides 11% discontinuation rate despite Semaglutide having a higher reported nausea incidence at 44%
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reduce appetite, slow digestion, and support blood sugar regulation
Moreover, the results demonstrated a significant upregulation of Sqstm1 (P62, which is inversely related to autophagic activity) protein in the HFD group, suggesting that the autophagic process might be hindered [55]
Cutando A, Montero J, Diego RG de, Ferrera MJ, Lopez-Valverde A
For business models, this manifests as high churn
Here's why that's both fantastic and frightening